vimarsana.com

Page 255 - புதியது ப்ராடக்ட்ஸ் மற்றும் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TEGNA Expands VERIFY to Stop the Spread of Disinformation, Announces Appointment of Managing Editor

Press release content from Business Wire. The AP news staff was not involved in its creation. TEGNA Expands VERIFY to Stop the Spread of Disinformation, Announces Appointment of Managing Editor January 25, 2021 GMT TEGNA names Jonathan Forsythe managing editor, VERIFY. (Photo: Business Wire) TYSONS, Va. (BUSINESS WIRE) Jan 25, 2021 TEGNA Inc. (NYSE: TGNA) today announced it is expanding VERIFY to help combat disinformation, and has named Jonathan Forsythe managing editor responsible for leading VERIFY’s editorial growth across all platforms. TEGNA names Jonathan Forsythe managing editor, VERIFY. (Photo: Business Wire) Since its creation in 2015, TEGNA stations’ VERIFY reporting has fought misinformation and disinformation and helped viewers and users distinguish between true and false information, with traffic to VERIFY content on stations’ websites increasing 423 percent in 2020 (source: Google Analytics). The VERIFY team, with help from questions submitted by viewers,

SPI Energy Begins Construction of Solar Plant in Oahu, Hawaii

Altais Completes Leadership Team with Three Board Members Reflecting Gender, Ethnic, Geographical and Medical Specialty Diversity

Press release content from PR Newswire. The AP news staff was not involved in its creation. Altais Completes Leadership Team with Three Board Members Reflecting Gender, Ethnic, Geographical and Medical Specialty Diversity January 25, 2021 GMT (PRNewsfoto/Altais) SAN FRANCISCO, Jan. 25, 2021 /PRNewswire/ Altais, Inc., a healthcare services start-up, today announced it has appointed three members to its board of directors, completing its seven-member board. The innovative healthcare services company is pioneering integrated, scalable technology solutions and business models that are designed to cultivate the health and well-being of physicians, patients and the clinical community. Altais’ strategy is to support independent physician practices by helping them deliver high-quality patient care and better health outcomes at lower costs, while promoting the providers’ own well-being and professional gratification.

Amadis Appoints Fabrice Grenier as Business Architect, Global Lead

Press release content from Business Wire. The AP news staff was not involved in its creation. Amadis Appoints Fabrice Grenier as Business Architect, Global Lead January 25, 2021 GMT Amadis Business Architect, Global Lead, Fabrice Grenier (Photo: Business Wire) MONTREAL & PARIS (BUSINESS WIRE) Jan 25, 2021 Amadis, the global payment software and consulting services provider, today announced the appointment of Fabrice Grenier as its Business Architect, Global Lead, focusing on EMEA (Europe, Middle East and Africa). He will be responsible for driving strategic initiatives and building strong partnerships, leveraging the unique AGNOS (EMV level 2 stack) and ARKOS (payment acceptance solution based on nexo standard) product lines, along with the Amadis One (SoftPOS / Tap2Phone / TapOnPhone) payment software framework.

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China

Press release content from Business Wire. The AP news staff was not involved in its creation. EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China January 25, 2021 GMT HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass. (BUSINESS WIRE) Jan 25, 2021 EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT ® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). iMCD is a rare, life-threatening and debilitat

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.